electroCore Announces Issuance of Two New U.S. Patents
ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents related to its non-invasive vagus nerve stimulation (nVNS) technology to electroCore, including the following patents:
Related news for (ECOR)
- electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
- electroCore’s Truvaga™ Now Works with the Apple Health app
- electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times
- electroCore Extends VA Contract for Five Years
- electroCore Announces Full Year 2024 Financial Results